If recruitment and retention matter, site satisfaction must be treated as a prerequisite. In this Journal for Clinical Studies article, Brian Mallon explains why start-up success is shaped by human factors, not technolog...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
Practical considerations for managing cell and gene therapy supply chains
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
IMI Mobilise-D: The next generation of mobility research
In this article from International Pharmaceutical Industry, Gerard Quinn, VP, IT Innovation and Informatics, provides an overview on the Innovative Medicines Initiative (IMI) funded Mobilise-D project, which aims to develop a comprehensive system to analyse people’s gait using digital technologies, including sponsors worn on the body.
-
Devices regulation offers opportunities and challenges for medtech
In this piece from the Irish Times, Cynthia Nolte, Director, Regulatory Affairs, Strategic Regulatory Services outlines that while there are challenges with the EU Medical Devices Regulation, the requirements do provide manufacturers with an opportunity to audit portfolios and eliminate unprofitable products.
-
AI has the power to revolutionise drug discovery and design
In this article from the Irish Times, Gerard Quinn, VP of IT Innovation and Informatics provides insight on how artificial intelligence can support the drug development process in order to deliver new treatments to more people, faster.
-
Decoding pandemic precision: From SARS-CoV-2 to influenza vaccination strategies
The need for public health officials to be able to model the spread of infectious diseases has never been more apparent than in the early days of the SARS-CoV-2 pandemic, but what needs to change? Read the article by ICON epidemiologist Dr. Richard Pitman in Open Access Government.
-
Shaking it up: The partnership paradigm in clinical research
Jeff James, Executive Vice President, Alliance Management, explores how outsourcing methodologies between large pharmaceutical companies and CROs have rapidly evolved across the healthcare and clinical research landscape.
Read the article on page 13 of the December issue of PharmaTimes.
-
Evolution in the outsourcing of clinical research
Partnership is an increasingly important criterium for bio/pharmaceutical sponsors as they seek more bespoke solutions and the flexibility of tailored, blended outsourcing models.
DiPietro, M. Elaboration, Expansion, and Evolution in Outsourcing of Clinical Research. Pharmaceutical Technology 2023 47 (12) 31–33
-
Implications of regulatory and FDA guidance on diversity, equity and inclusion on clinical research study sites
Following discussions at the 2023 Global Site Solutions Summit, Missy Gottschlich, Director of Site Networks for Accellacare, provides key insights on how sites can implement regulatory guidelines on diversity, equity and inclusivity in this article in pharmaphorum.
